Moteur de recherche d’entreprises européennes

Financement de l’UE (15,2 M €) : SORTIE-CVD Hor01/04/2026 Programme de recherche et d'innovation de l'UE « Horizon »

Vue d’ensemble

Texte

SORTIE-CVD

"EXIT-CVD aims to fundamentally transform cardiovascular disease (CVD) management by enabling early, personalized, and equitable interventions across the CVD continuum. Recognizing CVD as a dynamic progression, from risk factors to heart failure and premature death, EXIT-CVD identifies and operationalizes strategic ""exit points"" where disease trajectories can be disrupted. Through a multidisciplinary, public-private partnership involving academia, Medtech, pharma, SMEs, and patient organizations, the project will integrate state-of-the-art diagnostics (e.g., photon-counting CT, AI-enhanced wearables), digital monitoring, regenerative therapies, and advanced imaging-guided interventions. Innovations are embedded in a digitally enabled, FAIR-compliant data platform aligned with the European Health Data Space (EHDS), ensuring real-world scalability and regulatory readiness. EXIT-CVD rigorously applies implementation science through the frameworks RE-AIM (Reach, Effectiveness, Adoption, Implementation, Maintenance) which evaluates interventions along five core dimensions relevant to health systems uptake, and PROCTOR (Implementation Outcomes Framework) which focuses on concrete metrics such as acceptability, feasibility, fidelity, and cost. Additionally, EXIT-CVD adopts an equity-by-design approach to overcome persistent health disparities. Clinical studies target early detection (e.g., wearable blood pressure and AI-Electrocardiogram monitoring), intermediate stratification (e.g., imaging-guided Percutaneous Coronary Intervention (PCI) with Photon-Counting Computed Tomography (PCCT)), and late-stage recovery (e.g., engineered heart muscle transplantation and minimally invasive cardiac surgery supported by mechanical circulatory devices). By co-creating with patients and systematically addressing socioeconomic, gender, and digital access gaps, EXIT-CVD envisions a future where heart disease is not a terminal continuum but a preventable and reversible condition. This project will deliver validated, sustainable, and equitable innovations, positioning Europe at the forefront of cardiovascular health transformation."


Abiomed Europe GmbH 0,00 €
Academisch Ziekenhuis Groningen 2 601 957 €
Astrazeneca AB 0,00 €
BGP Products Operations GmbH 0,00 €
Bridg OÜ 188 193 €
Cardio Med Srl 274 560 €
Centro Cardiologico Monzino 726 198 €
Circle Cardiovascular Imaging Inc. 0,00 €
Cogstack Ltd. 46 500 €
Corbotics B.V. 260 000 €
Cordys Analytics B.V. 254 800 €
Ente Ospedaliero Cantonale 92 633 €
Fundacio de Gestio Sanitaria de L'Hospital de La Santa Creu i Sant Pau 425 760 €
GE Precision Healthcare LLC 0,00 €
Heartbeam Inc. 0,00 €
Huawei Technologies OY (Finland) CO Ltd. 0,00 €
Huawei Telekomünikasyon Dis Ticaret Ltd. Şti. 0,00 €
Iqvia Solutions B.V. 637 000 €
Johnson & Johnson Medical B.V. 0,00 €
Katholieke Universiteit Leuven 171 935 €
King's College London 178 208 €
Klinikum DER Universitaet ZU Koeln 75 000 €
London School of Economics and Political Science 556 000 €
Medtronic Iberica SA 1 089 900 €
Megi Health d.o.o. 46 500 €
Narodowy Instytut Kardiologii Stefana Kardynala Wyszynskiego - Panstwowy Instytut Badawczy 274 560 €
Novartis Pharma B.V. 0,00 €
Onsentia Ltd. 88 271 €
Philips Electronics Nederland B.V. 1 076 531 €
Philips GmbH 1 153 875 €
Philips Nederland B.V. 289 000 €
Politecnico Di Milano 71 385 €
Repairon GmbH 0,00 €
Sanofi-Aventis Deutschland GmbH 0,00 €
SE de Cardiologie 359 000 €
Siemens Healthineers AG 659 850 €
Stichting VrouwenHart 29 175 €
Technische Universiteit Eindhoven 75 286 €
Universita Degli Studi Di Pavia 47 019 €
Universitair Medisch Centrum Utrecht 2 100 678 €
Varsinais-Suomen Hyvinvointialue 270 675 €
Xvivo Perfusion AB 41 730 €
Zoll CMS GmbH 1 036 655 €

https://cordis.europa.eu/project/id/101253160

Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.